ATXI - Avenue Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.85
-0.06 (-1.53%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close3.91
Open3.90
Bid2.76 x 3200
Ask4.45 x 900
Day's Range3.83 - 4.03
52 Week Range3.28 - 8.58
Volume51,952
Avg. Volume42,443
Market Cap40.629M
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)-2.62
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Avenue Therapeutics to Participate in JMP Securities Life Sciences Conference

    NEW YORK, June 19, 2018-- Avenue Therapeutics, Inc., a specialty pharmaceutical company focused on the development and commercialization of intravenous tramadol, today announced that Lucy Lu, M.D., President ...

  • Zacks Small Cap Research8 days ago

    ATXI: KOL Call with Drs. Singla and Minkowitz on IV Tramadol

    Avenue Therapeutics (ATXI) hosted a moderated discussion on tramadol on June 11 which featured two key opinion leaders (KOLs) in the space. The participants were Dr. Neil Singla and Dr. Harold Minkowitz. Dr. Singla brings a long history developing analgesic medicines to the discussion.

  • GlobeNewswire14 days ago

    Avenue Therapeutics to Host Key Opinion Leader Call on Intravenous (IV) Tramadol for the Management of Postoperative Pain

    Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced that it will host a Key Opinion Leader (KOL) call on intravenous (IV) tramadol for the management of postoperative pain on Monday, June 11, 2018, at 11 a.m. EDT. The call will feature a moderated discussion with key opinion leaders Neil Singla, M.D., Lotus Clinical Research, and Harold Minkowitz, M.D., HD Research Corporation, who will discuss the unmet medical need and potential role of IV tramadol in the management of postoperative pain. Drs. Singla and Minkowitz will be available to answer questions following the conclusion of the discussion.

  • ACCESSWIRE28 days ago

    Blog Exposure - Avenue Therapeutics Reported Positive Results from Pivotal Phase-3 Trial of IV Tramadol

    LONDON, UK / ACCESSWIRE / May 23, 2018 / If you want access to our free research report on Avenue Therapeutics, Inc. (NASDAQ: ATXI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ATXI as the Company's latest news hit the wire. On May 21, 2018, the Company announced that its first pivotal Phase-3 trial assessing IV tramadol for treatment of patients with moderate to moderately severe postoperative pain following bunionectomy surgery achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours (SPID48) compared to placebo. Active-Investors.com is currently working on the research report for Taro Pharmaceutical Industries Ltd (NYSE: TARO), which also belongs to the Healthcare sector as the Company Avenue Therapeutics.

  • Benzingalast month

    Benzinga Pro's 5 Stocks To Watch Today

    Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Fibrocell Science Inc (NASDAQ: FCSC ) stock gained ...

  • GlobeNewswirelast month

    Avenue Therapeutics Announces Positive Topline Phase 3 Data for Intravenous Tramadol in the Management of Postoperative Pain

    Avenue Therapeutics, Inc. (ATXI) (“Avenue”), a company focused on the development and commercialization of intravenous (IV) tramadol, today announced that its first pivotal Phase 3 trial of IV tramadol achieved the primary endpoint of a statistically significant improvement in Sum of Pain Intensity Difference over 48 hours (SPID48) compared to placebo in patients with moderate to moderately severe postoperative pain following bunionectomy surgery. In addition, the trial met its key secondary endpoints and demonstrated a clear dose response.

  • Zacks Small Cap Researchlast month

    ATXI: 1Q:18 Update Confirms Timeline

    By John Vandermosten, CFA NASDAQ:ATXI Avenue Therapeutics (NASDAQ:ATXI) circulated a press release and their form 10-K with their first quarter 2018 financial results on May 3rd. Total expenses for the ...

  • GlobeNewswire2 months ago

    Avenue Therapeutics Reports First Quarter 2018 Financial Results and Recent Corporate Highlights

    NEW YORK, May 03, 2018-- Avenue Therapeutics, Inc., a company focused on the development and commercialization of intravenous tramadol, today reported financial results and recent corporate highlights ...

  • Zacks Small Cap Research2 months ago

    ATXI: No Pain? We See a Gain; Developing Tramadol

    Avenue Therapeutics (ATXI) is developing IV tramadol for postoperative pain. Avenue has licensed a patented administration of IV tramadol that is able to limit side effects and provide a solution for moderate to severe pain which avoids many of the risks of opioids and non-steroidal anti-inflammatory drugs (NSAIDs). The drug also allows for transition to step down therapy with oral tramadol, which mirrors the pharmacokinetic, side effect profile and pain control of the IV form.

  • GlobeNewswire3 months ago

    Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for Intravenous Tramadol

    NEW YORK, March 28, 2018-- Avenue Therapeutics, Inc., a company focused on the development and commercialization of intravenous tramadol, today announced receipt of Notices of Allowance from the U.S. Patent ...

  • TheStreet.comlast year

    Here's the Latest on Four New Biotech IPOs

    Four biotech companies recently joined the Nasdaq.

  • 24/7 Wall St.last year

    IPOs This Week: A Single Offering on Tap After 8 IPOs Last Week

    Just one IPO is scheduled for the holiday-shortened week ahead following a week that saw 8 IPOs hit the public market, including unicorn Blue Apron.

  • Blue Apron Pricing To Heat Up Crazy IPO Week: Investing Action Plan
    Investor's Business Dailylast year

    Blue Apron Pricing To Heat Up Crazy IPO Week: Investing Action Plan

    The busiest week for IPOs so far this year will kick into high gear Wednesday, as a few new issues debut in the morning and several more price in the evening.